Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 2,701–2,800 of 3,116
Nouveaux médicaments de l’obésité : quelle pertinence ?
Bringer, J. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.02.008
Wu, J., Zheng, W., Qi, Q., He, C., Zhai, C., & Fan, H. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm51234 · Cited by 1
GLP-1-based multipharmacology: Biased signaling as a determinant of therapeutic efficacy
Li, W., Yan, J., Zhao, F., & Yang, D. (2026) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2026.07.001
Treatment of obesity: New drugs
Berti, S., Garelli, S., & Pagotto, U. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00330-7
Treatment of Clusters of Risks to Prevent Heart Failure
Bozkurt, B. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2023.12.008
Sztanek, F., Lőrincz, H., Harangi, M., & Nagy, A. C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71277 · Cited by 1
Babazadeh, D., Zhong, H., & Steinberg, F. M. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101753 · Cited by 1
Dziewierz, A., Kulicka, N., Stolarska, K., Ahmatovic, A., Domienik‐Karłowicz, J., Rulkiewicz, A., & Siudak, Z. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71017 · Cited by 1
Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 1 Diabetes
Buros‐Stein, A., PAULEY, M. E., & Snell‐Bergeon, J. K. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.003
Li, H., Zhu, Z., Wang, X., Du, M., Wei, R., Wang, C., Miao, J., & Cheng, L. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102070 · Cited by 2
Semaglutide and Risk of Pancreatic Cancer: A Meta‐Analysis of Randomised Trials
Chiang, C., Bahar, F., Chang, Y., Wang, T. H., Hsia, Y. P., & Chiang, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70980
New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases
Mushailov, V., & Radhakrishnan, J. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101133 · Cited by 2
Therapie-Update bei Adipositas
Gallwitz, B. (2025) · Info Diabetologie · doi:10.1007/s15034-024-5057-0
Bariatric surgery in the era of modern obesity pharmacotherapy
Zhao, A. Y., & Dash, S. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjag004
Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial
Verma, R., Verma, M., Park, B., Teoh, H., Quan, A., Connelly, K. A., & Hess, D. A. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001323
Quantifying myocardial oxygen consumption and efficiency with motion-resolved cardiac MRI
Huang, L.-T., Yang, C., Wang, G., Zhang, H., Zhang, R., Ho, H. H., Malagi, A., Huang, Y., Li, X., Yoosefian, G., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.ady6269
Nouvelles approches pharmacothérapeutiques pour la gestion de l’obésité
Sollier, C., & Jacobi, D. (2025) · Pratiques en nutrition · doi:10.1016/j.pranut.2025.01.009
Kidney Function and Mortality in Mexico: Prospective Study of 130,000 Adults
Aguilar-Ramirez, D. J., Tapia‐Conyer, R., Herrington, W. G., Ramírez-Reyes, R., Garcilazo‐Ávila, A., González-Carballo, C., Santacruz-Benítez, R., Bello‐Chavolla, O. Y., Bragg, F., Friedrichs, L. G., et al. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101398
“29,30 In this middle-income country, where overweight and obesity are very common, and diabetes is frequent and often with high levels of glycemia, decreased kidney function resulted in a substantially increased risk of premature mortality, with the largest absolute excess risk observed in those…”
V CardioMIR: el Congreso de los Jóvenes Cardiólogos
Monterde, E. M., Rodríguez, A. J. W., Duran, Ö., & Laffond, A. E. (2024) · REC CardioClinics · doi:10.1016/j.rccl.2024.10.008
Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine
Guo, J., & Chen, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1933018
“The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in adults with established cardiovascular disease and overweight or obesity without diabetes (Lincoff et al., 2023).”
InfluentialPrévention secondaire chez le coronarien
Sorbets, E. (2025) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(25)48213-1
Kanjee, Z., Dearborn, J. L., Kumar, S., & Reynolds, E. E. (2024) · Annals of Internal Medicine · doi:10.7326/m23-3136
Cardiovascular safety of fixed-dose extended-release naltrexone/bupropion in clinical practice
Kyle, M., Burns, D., Murray, C. R., Watson, H. N., Swaney, J., Spevack, S. C., Leonhard, M. J., Simon, M. S., Moynihan, E., Lapane, K. L., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100169 · Cited by 1
Wang, J. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01959-3
“For semaglutide, large trials have now linked treatment to fewer new diagnoses of diabetes and to cardiovascular bene fi t in people with overweight or obesity and established cardiovascular disease [4].”
MODERN APPROACHES TO OBESITY TREATMENT WITH CONSIDERATION OF PHARMACOTHERAPY AND DIET THERAPY
Szkodziński, K., Jakubczyk, I., Maternia, J., Los, A. P. M., Majowicz-Czaszyńska, K. B., Pempuś, W., Król, N., Tomaszek, B., Blok, A., Wiater, D., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5735
Indennidate, C., Perencin, B., Maso, V. D., Buda, I., Candido, R., Sinagra, G., & Merlo, M. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02340-6 · Cited by 1
“STEP trial brought the attention to the strik - ing weight loss potential of semaglutide (> 15% in obese patients independent of diabetes status) and reduction in cardiovascular events thanks to [61] improvements in blood pressure, lipid profiles, inflammatory markers and in adipokine levels.”
Recurrent Weight Gain after Metabolic Bariatric Surgery (MBS): Emerging Insights on Kidney Function
Fazeli, S. A., Elamy, M. I., & Samarkhazan, H. S. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08406-2
“Landmark trials such as STEP-HFpEF and SELECT under-score their efficacy in complex populations, including post-bariatric patients, demonstrating significant weight loss and improved kidney outcomes [56 , 57 ].”
Glp-1 receptor agonists in obesity: Current evidence and clinical outcomes
Vidal, J. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.009
Alkabbani, W., Crisafulli, S., Paik, J. M., Tavakkoli, A., Bykov, K., Glynn, R. J., Wexler, D. J., & Patorno, E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70963 · Cited by 4
“Our results are consistent with findings from RCTs that showed an increased risk of gastrointestinal adverse events, particularly those related to impaired gastric motility, with GLP-1 RA use [4, 9–12].”
Boulet, J., & O’Meara, E. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.07.369
Giacalone, J. D., Elias, J., Le, J., Brancaccio, H., & Alberta, F. G. (2026) · Seminars in Arthroplasty JSES · doi:10.1016/j.sart.2026.151594
Disparities in Medication Treatment of Type 2 Diabetes and Obesity
Whooten, R., Allen, L., & Stanford, F. C. (2026) · PEDIATRICS · doi:10.1542/peds.2025-074840
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice
Ravindhran, B., Chetter, I., & Pymer, S. (2026) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2026.07.037
Mishra, A., mishra, P., Bajaj, S., Kalra, P., Mishra, V., Bhat, S., Patni, B., Abichandani, V. K., Farishta, F., Aggarwal, V., et al. (2026) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2026.100865
Osude, N., & Pagidipati, N. J. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.11.003
Automedicación con semaglutida en mujeres jóvenes
Machado, L., Machado, R., Cruz, L., Filho, L. C. R., Fox-Portillo, C., Fleita, G., Estigarribia, G., & Basiluk, Y. (2026) · Revista Científica de Salud "Ciensa" · doi:10.67123/v2n1o5
Chen, R., Liu, W., Zhao, X., Li, N., Liu, C., Zhou, P., Chen, Y., Yan, S., Li, J., Song, L., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01967-3
“…trial shows semaglutide reduces the risk of death, MI, and stroke by 20% in non-DM patients with pre-existing cardiovascular diseases and obesity [46], while in the SUM-MIT trial, tirzepatide reduces the risk of cardiovascular death and worsening heart failure (HF) by 38% in obese patients with…”
Shokravi, A., Singh, R., Sharma, S., Seth, J., & Mancini, G. B. J. (2026) · CJC Open · doi:10.1016/j.cjco.2026.02.008 · Cited by 1
Scuderi, G. R., Ganz, M. P., & Mont, M. A. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.10.027
Wen, S., Wang, C., Xu, Z., Chen, L., He, Y., Ren, Y., Yuan, Y., Li, Y., Dong, M., Gong, M., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03164-6 · Cited by 1
“Semaglutide 2.4 mg in SELECT (2023), targeting non-diabetic obesity with ASCVD, reduced MACE by 20% (HR 0.80, 95% CI 0.72–0.90, p 0.001), CV death by 15% (HR 0.85, 95% CI 0.71–1.01), and HF composites by 24% (HR 0.76, 95% CI 0.62–0.92), with obesity-driven subgroups showing enhanced effects [39].”
InfluentialRanič, I., Stanke, L., Jiravský, O., Heřman, D., Roubíček, T., Havránek, Š., Chovančík, J., Bulková, V., Matoulek, M., Tuka, V., et al. (2026) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2026.101931 · Cited by 1
“…pharmacotherapy may be phenotype-specific: the Metabolic phenotype may benefit from GLP-1 receptor agonists achieving substantial weight reduction [23,24]; the Advanced Neuro-hormonal/Inflammatory phenotype with elevated NT-proBNP may benefit from SGLT2 inhibitors [25] or anti-inflammatory…”
Kotanidis, C. P., Lincoff, A. M., & Shikora, S. A. (2025) · New England Journal of Medicine · doi:10.1056/nejmclde2413003
Self-citationPagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.032
Management of metabolic dysfunction and cardiovascular risk in patients with MASLD
Danpanichkul, P., Blaney, H. L., Perelli, J., Huerta, P., Idalsoaga, F. J., Arrese, M. A., Arab, J. P., Loomba, R. S., & Díaz, L. A. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.32 · Cited by 3
Ahmed, M. (2025) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.52.68.79
Continuity of care in obesity clinical care
Lesmes, I. B., García, J. M. F., Vilarrasa, N., Arroyo, V. R., de Hollanda, A., Cortés, G. B., & Ballesteros-Pomar, M. D. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.501658 · Cited by 1
Zheng, X., Huang, X., & Huang, Y. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.12.009
GLP-1RA pharmacokinetics and clinical effects: focus on cardiac, vascular, and glomerular structures
Barnaba, I., Massari, F., Ciccone, M. M., Caldarola, P., Campanella, C., Ricci, G., & Scicchitano, P. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2714849
Long-term management of body weight and physiological mechanisms of weight regain
Hu, T., & Bao, Y. (2026) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaf062 · Cited by 1
“Importantly, in the SELECT cardiovascular outcomes trial of 17604 adults with established atherosclerotic disease and no diabetes, 2.4 mg semaglutide reduced the risk of major adverse cardiovascular events by 20% compared with placebo after 34.2 months of follow-up (Lincoff et al., 2023 ).”
InfluentialBilato, C., Baratta, R., Luca, L. D., Luca, M. D., Fucili, A., Iacoviello, M., Sbraccia, P., & Busetto, L. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104872
Saavedra, J. M., Chen, A. S., Starr, K. N. P., & Batsis, J. A. (2026) · Obesity · doi:10.1002/oby.70203
AlTaweel, M., Almekhloof, S., Alsaad, A., Alotaibi, T., Alkhaldi, R., Alalawi, A., Alarfaj, A. A., Almannai, N., Almusaad, A., & KHASHWAYN, S. A. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.08.009
Fanizza, J. D., Moghaddam, A. S., & Atrash, A. (2026) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2026.112192 · Cited by 2
Nelson, R. A., Lai, Y.-C., Kil, S. H., Lee, H. S., Mortimer, J. E., & Wang, P. H. (2026) · The Oncologist · doi:10.1093/oncolo/oyag268 · Cited by 1
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
“Notably, in individuals with overweight or obesity and CV disease but without diabetes, semaglutide 2.4 mg was associated with a 20% reduction in major CV events (CV death, nonfatal myocardial infarction, or nonfatal stroke), accompanied by sustained long-term weight loss [50].”
InfluentialBeyond Weight Loss: Redefining MASLD Management Through Obesity Pharmacotherapy
Ravaioli, F. (2026) · European Medical Journal · doi:10.33590/emj/1463768r
Fioretti, F., Petrie, M. C., Dickert, N. W., & Butler, J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5086
Continuous glucose monitoring trajectories in patients with acute coronary syndrome
Expósito, A. D., Garcia-Ruiz, V., Castillo-Barnés, D., Ortíz, A., Larrubia-Valle, J. I., Molinero, A., Puyol-Ruiz, F., Barquero-Alegre, O., González-Aguado, N., Martín-Chaves, L., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03169-1
“In the SELECT trial, among overweight patients with established cardiovascular disease (mostly MI) without diabetes mellitus, semaglu-tide significantly reduced major cardiovascular events (MACE) [15].”
McCraw, C. D., Grayeb, D. R., Gupta, N., et al. (2026) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2026.2730537
Hsu, H.-C., Shih, L., Hou, Y., & Lu, K. (2026) · Biomolecules · doi:10.3390/biom16081155
Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Promises, Pitfalls, and the Path Forward
Eke, A. C. (2026) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000006021 · Cited by 1
Туркина, С. В. (2026) · Consilium Medicum · doi:10.26442/20751753.2026.5.203661
Batra, K., Khubchandani, J., Batra, R., & Ali, S. A. (2026) · Diabetology · doi:10.3390/diabetology7080144
“These agents improve glycemic control, promote clinically meaningful weight loss, reduce cardiovascular risk, and are increasingly incorporated into evidence-based management strategies for type 2 diabetes and obesity [25–27].”
Luo, G., Ding, D., Liu, M., Zhang, C., & Chen, L. (2026) · The Innovation Nutrition · doi:10.59717/j.xinn-nutri.2026.100032
A high-value, cross-continuum approach to heart failure: A narrative review
Potharazu, A. V., Mansour, A. I., Berkowitz, S., Bhatla, A., Feeser, S. A., Hill, P., Issa, J., Johnson, P., Segall, H., & Gilotra, N. A. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.07.003
Marx-Schütt, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00016-1
Li, H., Peng, S., & Lei, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1957367
Tarantini, G., Panza, A., Parma, R., & Mieghem, N. M. V. (2026) · Forensic Sciences Research · doi:10.3788/tfsr20260029
Li, J., Chandrashekar, A., Ravikumar, R., et al. (2025) · Pancreatology · doi:10.1016/j.pan.2025.12.021
Vergallo, R., & Liuzzo, G. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf535
Silvariño, R., Rico-Fontalvo, J. E., Villavicencio, V., Sánchez-Polo, V., & Rosa-Diez, G. J. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.m24000022
Comorbid Cardiovascular-Liver Disease Disparities: Current Understanding and Future Directions
Hafez, A. H., Nour, M., Ibrahim, R., Othman, J., Mohamed, M. R., Awad, K., Zanco, J., Serra, V. D. S. B., Abdelnabi, M., Elbsiony, M., et al. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02426-9
“GLP-1 receptor ago - nists and SGLT2 inhibitors should be selected according to established indications, the evidence for the individual agent, comorbidities, safety, patient preferences, and access [ 1 , 2 , 32–38 ].”
InfluentialDeaconu, L., Albai, O., Timar, B., Braha, A., Popescu, S., Sorescu, T., Gaiţă, L., Iordan, L., & Timar, R. Z. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124421
“…in People with Overweight or Obesity) trials showed significant decreases in major adverse cardiovascular events, including myocardial infarction and stroke, even in populations without diabetes, highlighting the key role of IR, obesity, and inflammation as modifiable indicators of CVD [14,15].”
Labate, A. M., Cimino, E., Giacomelli, L., Ettori, S., Oladeji, O. A., & Agosti, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146170 · Cited by 1
Neue Behandlungsmöglichkeiten der Adipositas
Heitlinger, E., & Keller, U. B. (2024) · doi:10.36000/hbt.2023.11.001
How the US National Institutes of Health is confronting health threats in a changing world
Marrazzo, J. M., Neuzil, K. M., & Bertagnolli, M. M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02576-5
Pedagogos, E., Chen, R., Nelson, A. J., Badve, S. V., Rasalam, R. R., & MacIsaac, R. J. (2026) · Internal Medicine Journal · doi:10.1111/imj.70647
Pendrey, A., Sierra, J. A. R., Lobo, F. A. A., Herrera, E. J. R., Muñoz, Y. M. F., & Sevilla‐Martir, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03702-4
“Its effects on inflammation, endothelial function, and atherosclerotic processes contribute to its cardiovascular and renal benefits [15, 16].”
Li, C. L., Lin, C., Li, Z., Lv, F., Yang, W., Ji, L., & Cai, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1859388 · Cited by 1
“…the included RCTs were primarily designed and powered to assess cardiovascular and metabolic outcomes, with cognitive disorders documented only as adverse events rather than prespecified primary endpoints (Lincoff et al., 2023; Heymsfield et al., 2021; Nissen et al., 2016; Marso et al., 2016).”
Lau, L. C., Lui, T. W. D., Wen, C., Zhu, L., Lin, S., Leung, T. K. C., Luk, M. H., Ping Keung, C. H. A. N., Cheung, A., Chiu, K. Y., et al. (2026) · Bone & Joint Open · doi:10.1302/2633-1462.77.bjo-2025-0359.r1
“23,24 GLP-1RAs are therefore a plausible weight loss intervention to optimize TKA candidates, and their potential perioperative efects may extend beyond weight reduction alone and may include metabolic and anti-infam-matory mechanisms.”
GLP-1 RA Eligibility in Reproductive-Age U.S. Women
Shi, I., Khan, S. S., Grobman, W. A., & Kazi, D. S. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc25-0040
The Ageing Adipose Paradox: Implications for Metabolic Health
Matar, D. B., Elahi, M. A., Nassar, W. K., Alotaibi, M. I., Murphy, D., Fakhoury, H. M. A., & Aljada, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71037 · Cited by 1
“Seventeen thousand six hundred and four patients entered SELECT; 2539 entered SURMOUNT-1 [109, 110].”
InfluentialMalmborg, M., El‐Chouli, M., Andersen, C. F., et al. (2025) · medRxiv · doi:10.1101/2025.05.05.25327040
Petermann-Rocha, F. E., Briones‐Valdivieso, C., Nazar, G., Sugg, D., Reyes‐Molina, D., Celis-Morales, C. A., Diaz‐Toro, F., & Deo, S. V. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70260
Cuatrecasas, G. (2026) · Atención Primaria · doi:10.1016/j.aprim.2026.103496
Cardiovascular diseases and diabetes—new focus on obesity
Dörr, R., Tschöpe, D., & Marx, N. (2025) · Herz · doi:10.1007/s00059-025-05320-2
Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis
Chen, Q.-X., Xiao-yu, Z., Wu, Q., Xie, J.-J., Xu, Y., Teng, F., & Guo, M. (2026) · Endocrine · doi:10.1007/s12020-026-04757-7 · Cited by 1
“…together, this event-based perspective complements prior studies by clarifying when BP reduction becomes large enough to influence clinical outcomes, thereby offering a more clinically meaningful understanding of the balance between antihypertensive benefit and the risk of overcorrection [ 32 ].”
Wilkinson, M. J., Padilla, E., Wang, Y., Raygani, S., Manoogian, E. N. C., Laing, K. L., Tong, K., Liu, L., Van, D. T., Nguyen, J. P., et al. (2026) · Obesity · doi:10.1002/oby.70228 · Cited by 2
“Pharmacotherapy for obesity can reduce hs-CRP [38, 40], but organ-level biomarkers of inflammation, such as in adipose tissue, have the potential to elucidate tissue-specific changes in inflammation and the underlying anti-inflammatory mechanisms occurring during treatments for obesity, from…”
Popa, E., Popa, A. E., Poroch, V., Schreiner, T. G., Slănină, A. M., Poroch, M., Hatneanu, A. M., Ungureanu, M. I., Petroaie, A. D., Bacușcă, A. I., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198738
Andersen, A. K., Mehdizavareh, H., Khan, A., Becher, T., Britsch, S., Britsch, M., Bøttcher, M., Winther, S., Rohde, P. D., Jensen, M. H., et al. (2026) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocag127 · Cited by 5
Weekly Journal Scan: SURMOUNT and MAINTAIN the summit: tirzepatide after successful bodyweight loss
Liuzzo, G., & Patrono, C. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag621
de Ferranti, S. D., Teng, J. E., Arslanian, S. A., Atz, A. M., Brothers, J. A., Cartoski, M. J., Freemon, D., Magge, S. N., Mahle, W. T., Mietus‐Snyder, M., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.107327 · Cited by 2
La medicina cardiometabolica nell’obesità
(2024) · il Diabete · doi:10.30682/ildia2304d
Prajapati, P., Shafi, N., Pachchipulusu, V., Fatima, N., Noorien, S., Biswas, S. K., Narula, A., Aishwarya, K., Prajapati, S. D., Patel, M. K., et al. (2025) · medRxiv · doi:10.1101/2025.09.01.25334855
Holmbäck, U. C., Grudén, S., Kuusk, S., Litorp, H., Englund, J., Söderhäll, A., Alderborn, G., & Forslund, A. (2026) · Scientific Reports · doi:10.1038/s41598-026-62003-6
“Furthermore, the ~ 10% lowering of LDL observed in the trial was larger than seen in much longer clinical trials in participants with similar characteristics using semaglutide 29 or tirzepatide 30 .”
Beyond weight gain toward healthy cardiometabolic aging in people with HIV
Wanjalla, C. N. (2026) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000001073
Ming, Q., & Li, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1914155
“…in People With Overweight or Obesity (SELECT), semaglutide 2.4 mg lowered the incidence of major adverse cardiovascular events among adults with overweight or obesity, established cardiovascular disease, and no diabetes, placing cardiovascular risk modification alongside weight reduction (11).”
InfluentialOchani, S. (2026) · Asia Pacific Journal of Public Health · doi:10.1177/10105395261465730
Mayne, K. J., Lee, M. M. Y., Sattar, N. A., & Herrington, W. G. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107193
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
